Validation of an NGS mutation detection panel for melanoma

Area of Science:

• Oncology
• Genetics
• Molecular Diagnostics

Background:

• Melanoma patient management relies on understanding tumor genotype.
• Identifying BRAF and c-KIT mutations guides targeted treatments.
• NRAS, GNAQ, or GNA11 mutations may indicate benefit from immunotherapy.

Purpose of the Study:

• To describe and validate an Ampliseq hotspot panel for melanoma mutation detection using next-generation sequencing (NGS).
• To evaluate the utility of NGS compared to traditional polymerase chain reaction (PCR) methods for melanoma genetic profiling.
• To assess the suitability of the NGS panel for clinical application with formalin-fixed paraffin-embedded (FFPE) samples.

Main Methods:

• Development of an Ampliseq hotspot panel for melanoma targeting clinically relevant mutations.
• Utilized the IonTorrent Personal Genome Machine (PGM) for NGS analysis.
• Validated the NGS panel on 151 melanoma cases (skin and uveal) and correlated results with PCR-based BRAF mutation assessment.

Main Results:

• Excellent agreement was observed between NGS and PCR for BRAF mutation status.
• NGS demonstrated broader mutation coverage, identifying some mutations missed by PCR.
• The identified rare mutations by NGS were of often unknown clinical significance for treatment decisions.

Conclusions:

• The described NGS panel is suitable for clinical use with FFPE samples for comprehensive melanoma genotyping.
• PCR methods remain a rapid, cost-effective option for initial BRAF mutation screening.
• NGS provides more extensive genetic information, potentially aiding in selecting alternative therapeutic strategies beyond BRAF/c-KIT targeted therapy.